PR Newswire Europe - U.S. Regulators Approve Cymbalta(R) for Treatment of Generalised Anxiety Disorder.
INDIANAPOLIS, February 26 /PRNewswire/ —
The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim announced today.
Related Results
Cymbalta contractCymbalta approvalCymbalta launch expectedCymbalta for GAD, Humira for Crohn’sCymbalta Approved for Fibromyalgia
The approval is based on the results of three randomized, double-blind, placebo-controlled studies in which the safety and efficacy of duloxetine in the treatment of GAD was studied in more than 800 non-depressed adults. In all studies, duloxetine significantly improved core anxiety symptoms as measured …
Read the rest of this article with a Free Trial at HighBeam Research.
